Sandwich ELISA, Biotin-labelled antibody
Serum, Plasma (EDTA, citrate, heparin)
At ambient temperature. Upon receipt, store the product at the temperature recommended below.
Store the complete kit at 2 8°C. Under these conditions, the kit is stable until the expiration date (see label on the box)
62.5 – 4 000 pg/ml
Limit of Detection
n = 8; CV = 4.3 %
n = 7; CV = 3.5 %
- It is intended for research use only
- The total assay time is less than 3 hours
- The kit measures STC2 in serum and plasma (EDTA, citrate, heparin)
- Assay format is 96 wells
- Standard is recombinant protein based
- Components of the kit are provided ready to use, concentrated or lyophilized
Bone and cartilage metabolism, Oncology
Stanniocalcin 2 (STC2) is a secreted, homodimeric glycoprotein that is expressed in a wide variety of tissues including muscle, heart, pancreas, kidney, spleen, prostate, small intestine, colon and peripheral blood leukocytes. The encoded protein has 10 of its 15 cysteine residues conserved among stanniocalcin family members and is phosphorylated by casein kinase 2 exclusively on its serine residues. Its C-terminus contains a cluster of histidine residues which may interact with metal ions.
STC2 may have autocrine or paracrine functions. The protein may play a role in the regulation of renal and intestinal calcium and phosphate transport, cell metabolism, or cellular calcium/phosphate homeostasis. Constitutive overexpression of human stanniocalcin 2 in mice resulted in pre- and postnatal growth restriction, reduced bone and skeletal muscle growth, and organomegaly. STC2 is also known to be involved in the regulation of unfolded protein response in the endoplasmic reticulum (ER), as well as in the regulation of cell proliferation under hypoxic conditions.
In addition, a series of recent studies have shown that STC2 is also associated with cancer development. The expression of STC2 is up-regulated in several cancer types, including gastric cancer, neuroblastoma, colon cancer, prostate cancer and breast cancer. Expression of STC2 gene is induced by estrogen and altered in some breast cancers. It was found the significant difference in the activity of the MAPK signaling pathway between cisplatin sensitive and resistant cervical cancer cells, and that STC2 could regulate the activity of the MAPK signaling pathway. This suggesting an important role for STC2 in the development and progression of cancers but despite these pioneering studies, the clinical significance and molecular mechanism of STC2 in cancers, however, still remain controversial and need to be further elucidated.